PRODUCT PIPELINE
OQP is focused on identifying the most effective combinations of our antigen-specific antibodies with other cytotoxic and immunomodulatory agents to enhance the clinical benefit of tumor-specific immunity in ovarian cancer, pancreatic cancer and metastatic breast cancer.
The OQP technology platform includes a number of monoclonal antibodies, each specifically targeting tumorigenic proteins such as CA-125, MUC-1, PSA, and Her2/neu, and has potential for development in multiple indications.
OQP believes that developing combination protocols utilizing our immuno-stimulatory antibodies, chemotherapeutic agents, checkpoint inhibitors, PARP inhibitors, and immune adjuvants, will lead to important clinical advances for patients suffering from ovarian and pancreatic cancer, and breast cancer.
Clinical trials using OQP's lead product, oregovomab, in more than 950 ovarian cancer patients, indicate chemo-enhanced immunotherapy results in a more vigorous immune response associated with improved survival compared to mono-immunotherapy or chemotherapy alone.